Our mission is to discover, develop, and commercialize medicines that improve the lives of patients by combining the potential of high-value GPCR drug targets with the power of state-of-the-art small molecule drug discovery technologies. Septerna’s Native Complex™ Platform is the engine that will make this happen, moving ideas for disease-modifying therapies from possibility to reality.

Leading a team of biologists in the discovery of novel therapies for the treatment of cardiomyopathies and other forms of heart disease. Transitioning from MyoKardia following its acquisition by Bristol Myers Squibb in November 2020.

To change the world for people with serious cardiovascular diseases through bold and innovative science, MyoKardia is pioneering a precision medicine approach to treating cardiomyopathies and other forms of heart failure that results from biomechanical defects in cardiac muscle contraction.

Drug Discovery R&D.Responsible for all aspects of Numerate’s experimental biology strategy. PI on two NIH SBIR grant funded projects (cardiac arrhythmias and bone disorders).Numerate seeks to overcome major challenges in drug discovery by applying artificial intelligence (AI), at cloud scale, to the problems of small-molecule drug design. Numerate was acquired by Valo Health (https://www.valohealth.com).

Drug Discovery R&DDepartment: Molecular & Cellular BiologyExpertise: Small Molecule Drug Discovery, Molecular Pharmacology, Cell Biology, Biochemistry, Discovery Collaborations w. Partner Companies, Outsourced ResearchRole: Group Leader; Project Team LeaderTherapeutic Expertise: Cardiovascular, Respiratory

Member of expert panel evaluating grant proposals for European Union FP7 Program

MS student in Chemistry (1989-1990), worked on the synthesis and characterization of analogs of vasopressin and oxytocin; modification of the parent peptides with biotin and photoreactive groups to obtain tools for the biochemical characterization of the respective receptors. Continued work as a PhD student in Biochemistry (1990-1994) to use those tools for protein-chemical characterization of the guinea pig oxytocin receptor.